Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Alpha Kinase 1 T237M mutant (ALPK1 T237M) is a gain-of-function mutation of the ALPK1 protein, where threonine at position 237 is replaced by methionine. This mutation leads to constitutive activation of the NF-κB signaling pathway, even in the absence of the canonical bacterial ligand ADP-heptose. The mutant protein also exhibits altered ligand specificity responding abnormally to endogenous nucleotide sugars. This results in increased production of pro-inflammatory cytokines and is associated with ROSAH syndrome.
Constitutive activation of NF-κB signaling pathway via TIFA-dependent activation in the absence of its canonical ligand. Aberrant recognition of endogenous nucleotide sugars.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha Kinase 1 T237M Mutant (ALPK1 T237M).